Axovant gene therapies ltd. (AXGT)
Balance Sheet / Yearly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Assets
Current assets:
Cash and cash equivalents

27,800

60,255

84,200

106,999

84,900

90,726

92,934

154,337

188,251

235,373

297,858

212,573

200,405

229,664

252,657

276,251

299,998

320,211

331,069

0

Prepaid expenses and other current assets

3,621

4,503

5,657

5,859

4,883

4,095

7,448

2,174

2,095

4,587

7,627

6,457

4,234

4,105

3,300

4,865

3,819

2,031

27

4

Income tax receivable

1,988

2,071

1,916

1,726

1,580

1,530

1,616

1,751

2,790

2,813

1,224

658

938

675

796

970

-

-

-

0

Deferred tax assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

273

-

-

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

1,104

Total current assets

33,421

66,829

91,749

114,584

91,402

96,351

101,998

158,262

193,136

242,773

306,709

219,688

205,577

234,444

256,753

282,086

303,817

322,515

331,096

1,108

Long-term investment

5,871

5,871

5,871

5,871

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current assets

46

46

46

973

3,449

4,324

3,784

0

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease right-of-use assets

1,946

2,237

2,664

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment, net

980

1,081

1,115

1,278

1,365

1,513

1,802

2,524

3,232

3,367

2,294

142

159

103

106

89

61

33

16

9

Deferred tax assets

-

-

-

-

-

-

-

-

0

0

0

2,709

323

40

323

323

-

-

-

-

Deferred tax assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Deferred tax assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

115

-

-

Deferred tax assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

182

-

Total assets

42,264

76,064

101,445

122,706

96,216

102,188

107,584

160,786

196,368

246,140

309,003

222,539

206,059

234,587

257,182

282,498

303,878

322,663

331,294

1,117

Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable

347

1,567

2,896

1,698

1,018

1,817

1,431

3,949

1,032

2,860

8,547

8,551

9,251

9,510

2,843

622

3,556

697

756

403

Due to Roivant Sciences Ltd., Roivant Sciences, Inc. and Roivant Sciences GmbH

-

-

-

-

693

2,859

2,156

1,011

1,360

4,242

4,466

2,919

4,947

2,706

2,218

1,814

1,839

2,458

1,629

2,307

Accrued expenses

20,334

21,427

27,698

20,619

22,911

24,315

25,133

31,862

34,935

33,794

38,041

34,796

25,397

16,427

11,872

8,319

5,398

-

-

1,158

Current portion of operating lease liabilities

1,156

1,672

1,586

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current portion of long-term debt

8,900

22,600

21,855

21,182

20,600

20,009

14,791

9,753

4,814

-

-

0

-

-

-

-

-

-

-

-

Accrued legal fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

232

869

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,707

1,063

-

Contingent payment liability

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5,000

5,000

5,000

-

0

Income tax payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

99

284

252

-

Total current liabilities

30,688

47,279

54,035

43,499

45,205

49,000

43,511

46,575

42,141

40,896

51,054

46,266

39,595

28,643

16,933

15,755

15,892

10,378

4,569

3,868

Operating lease liabilities, net of current portion

77

3

525

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term debt

6,452

11,742

17,533

22,994

28,251

33,309

38,247

42,925

47,579

52,068

51,752

51,436

-

-

-

0

-

-

-

-

Contingent payment liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

5,000

Contingent payment liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,000

-

Total liabilities

37,217

59,024

72,093

66,493

73,456

82,309

81,758

89,500

89,720

92,964

102,806

97,702

39,595

28,643

16,933

15,755

15,892

10,378

9,569

8,868

Commitments and contingencies (Note 11)

-

-

-

-

-

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

Shareholders’ equity:
Common shares, par value $0.00001 per share, 1,000,000,000 shares authorized, 22,791,669 and 22,779,891 issued and outstanding at December 31, 2019 and March 31, 2019, respectively

0

0

0

0

2

1

1

0

1

1

1

1

1

1

1

1

1

1

1

1

Common shares subscribed

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1

1

Additional paid-in capital

746,845

744,506

743,486

741,318

699,064

661,980

633,979

628,111

637,487

626,777

610,811

459,601

448,773

440,442

432,495

420,934

412,506

373,450

370,830

13,296

Accumulated deficit

-741,996

-727,957

-714,100

-686,016

-676,970

-642,674

-608,839

-556,951

-531,632

-473,730

-404,644

-335,143

-282,310

-234,499

-192,247

-154,192

-124,521

-61,166

-49,105

-21,047

Accumulated other comprehensive income

198

491

-61

911

664

572

685

126

792

128

29

378

-

-

-

0

-

-

-

-

Total shareholders’ equity

5,047

17,040

29,352

56,213

22,760

19,879

25,826

71,286

106,648

153,176

206,197

124,837

166,464

205,944

240,249

266,743

287,986

312,285

321,725

-7,751

Total liabilities and shareholders’ equity

42,264

76,064

101,445

122,706

96,216

102,188

107,584

160,786

196,368

246,140

309,003

222,539

206,059

234,587

257,182

282,498

303,878

322,663

331,294

1,117